Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome

Diabetes Care - Tập 24 Số 4 - Trang 683-689 - 2001
Bo Isomaa1, Peter Almgren2, Jaakko Tuomilehto3, Björn Forsén4, Kaj Lahti5, Michael J. Nissen6, Marja‐Riitta Taskinen3, Leif Groop7
1Department of Internal Medicine, Jakobstad Hospital, Jakobstad, Finland
2Wallenberg laboratory, University of Lund, Malmö, Sweden
3Department of Medicine, Helsinki University Hospital, Helsinki
4Närpes Health Center, Närpes
5Vasa Health Center
6Department of Medicine, Vasa Central Hospital, Vasa, Finland
7Department of Endocrinology, Lund University, Malmo, Sweden

Tóm tắt

OBJECTIVE—To estimate the prevalence of and the cardiovascular risk associated with the metabolic syndrome using the new definition proposed by the World Health Organization (WHO).

RESEARCH DESIGN AND METHODS—A total of 4,483 subjects aged 35–70 years participating in a large family study of type 2 diabetes in Finland and Sweden (the Botnia study) were included in the analysis of cardiovascular risk associated with the metabolic syndrome. In subjects who had type 2 diabetes (n = 1,697), impaired fasting glucose (IFG)/impaired glucose tolerance (IGT) (n = 798), or insulin-resistance with normal glucose tolerance (NGT) (n = 1,988), the metabolic syndrome was defined as presence of at least two of the following risk factors: obesity, hypertension, dyslipidemia, or microalbuminuria. Cardiovascular mortality was assessed in 3,606 subjects with a median follow-up of 6.9 years.

RESULTS—In women and men, respectively, the metabolic syndrome was seen in 10 and 15% of subjects with NGT, 42 and 64% of those with IFG/IGT, and 78 and 84% of those with type 2 diabetes. The risk for coronary heart disease and stroke was increased threefold in subjects with the syndrome (P < 0.001). Cardiovascular mortality was markedly increased in subjects with the metabolic syndrome (12.0 vs. 2.2%, P < 0.001). Of the individual components of the metabolic syndrome, microalbuminuria conferred the strongest risk of cardiovascular death (RR 2.80; P = 0.002).

CONCLUSIONS—The WHO definition of the metabolic syndrome identifies subjects with increased cardiovascular morbidity and mortality and offers a tool for comparison of results from different studies.

Từ khóa


Tài liệu tham khảo

Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595–1607, 1988

Kylin E: Studien ueber das Hypertonie-Hyperglykämie-Hyperurikämiesyndrom. Zentralblatt fuer Innere Medizin 44:105–127, 1923

Björntorp P: Abdominal obesity and the metabolic syndrome (Review). Ann Med 24:465–468, 1994

Groop L, Ekstrand A, Forsblom C, Widén E, Groop PH, Teppo AM, Eriksson J: Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36:642–647, 1993

Mykkänen L, Zaccaro DJ, Wagenknecht LE, Robbins DJ, Gabriel M, Haffner SM: Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the Insulin Resistance Atherosclerosis Study. Diabetes 47:793–800, 1998

Yudkin JS: Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? (Review) Diabetes Care 22 (Suppl. 3):C25–C30, 1999

Hanefeld M, Leonhardt W: Das Metabolische Syndrom. Dt Gesundh.-Wesen 36:545–551, 1981

DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease (Review). Diabetes Care 14:173–194, 1991

Descovich GC, Benassi B, Cancelli V, D’Addato S, De Simone, Dormi A: An epidemic view of the plurimetabolic syndrome. In Diabetes, Obesity and Hyperlipidemias. V. The Plurimetabolic Syndrome Crepaleli G, Tiengo A, Manzato E, Eds. Amsterdam, Netherlands, Elsevier Science, 1993, p. 31–39

Bouchard C, Perusse L: Genetics of causes and manifestations of the metabolic syndrome. In Diabetes, obesity and hyperlipidemia: V. The plurimetabolic syndrome Crepaldi G, Tiengo A, Manzato E, Eds., Amsterdam, Elsevier Science, 1993, p. 67–74

Kaplan NM: The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149:1514–1520, 1989

Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Shirit A, Fuchs Z: Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest 75:807–817, 1985

Haffner S, Valdez R, Hazuda H, Mitchell B, Morales P, Stern M: Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41:715–722, 1992

Balkau B, Charles MA: Comments on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442–443, 1999

Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M: Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 47:1643–1649, 1998

Rantala AO, Kauma H, Lilja M, Savolainen MJ, Reunanen A, Kesäniemi YA: Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med 245:163–174, 1999

Alberti KGMM, Zimmet PZ, for the WHO Consultation: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 15:539–553, 1998

Groop L, Forsblom C, Lehtovirta M, Tuomi T, Karanko S, Nissén M, Ehrnström BO, Forsén B, Isomaa B, Snickars B, Taskinen MR: Metabolic consequences of a family history of NIDDM (the Botnia Study): evidence for sex-specific parental effects. Diabetes 45:1585–1593, 1996

Tuomi T, Carlsson Å-L, Li H, Cano L, Isomaa B, Miettinen A, Nissén M, Ehrnström B-O, Forsén B, Lahti K, Forsblom C, Saloranta C, Taskinen MR, Groop L: Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150–157, 1999

Lehto M, Tuomi T, Mahtani M, Widén E, Forsblom C, Gullström M, Sarelin L, Isomaa B, Kanninen T, Lehtovirta M, Hyrkkö A, Orho M, Kirby A, Brettin T, Thomas J, Duyk G, Lander ES, Taskinen M-R and Groop L: Characterisation of the MODY3 phenotype, early-onset diabetes caused by an insulin secretion defect. J Clin Invest 99:582–591, 1997

Rose G, Blackburn H: Cardiovascular Survey Methods . Geneva, World Health Organization, 1968 (monogr. no. 56)

Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A: Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 90:583–612, 1994

Haffner SM, Miettinen H, Stern MP: The homeostasis model in the San Antonio Heart Study. Diabetes Care 20:1087–1092, 1997

Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifugation. Clin Chem 18:499–502, 1972

Vanhala MJ, Kumpusalo EA, Pitkäjärvi TK, Takala JK: Metabolic syndrome in a middle-aged Finnish population. J Cardiovasc Risk 4:291–295, 1997

Liese AD, Mayer-Davis EJ, Tyroler HA, Davis CE, Keil U, Schmidt MI, Brancati FL, Heiss G: Familial components of the multiple metabolic syndrome: the ARIC Study. Diabetologia 40:963–970, 1997

Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type II diabetes. Diabetologia 43:148–155, 2000

Yki-Järvinen H: Glucose toxicity. Endocrinol Rev 13:415–431, 1992

Randle PJ, Garland PB, Hales CN, Newsholme EA: The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet i:785–789, 1963

Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM (Review). Diabetes 46:3–10, 1997

Taskinen MR, Lahdenperä S, Syvänne M: New insights into lipid metabolism in non-insulin-dependent diabetes mellitus. Ann Med 28:335–340, 1996

Hodge AM, Dowse GK, Zimmet PZ: Microalbuminuria, cardiovascular risk factors, and insulin resistance in two populations with a high risk of type 2 diabetes mellitus. Diabet Med 13:441–449, 1996

Zavaroni I, Bonini L, Gasparini P, Zuccarelli A, Dall’Aglio E, Barilli L, Cioni F, Strata A, Reaven GM: Dissociation between urinary albumin excretion and variables associated with insulin resistance in a healthy population. J Intern Med 240:151–156, 1996

Jensen JS, Borch-Johnsen K, Feldt-Rasmussen B, Appleyard M, Jensen G: Urinary albumin excretion and history of myocardial infarction in a cross-sectional study of 2,613 individuals. J Cardiovascular Risk 4:121–125, 1997

Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS: Urinary albumin excretion: an independent predictor of ischemic heart disease. Arterioscl Thromb Vasc Biol 19:1992–1997, 1999

Kuusisto J, Mykkänen L, Pyörälä K, Laakso M: Hyperinsulinemic microalbuminuria: a new risk indicator for coronary heart disease. Circulation 91:831–837, 1995

Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 157:1413–1418, 1997

Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B: Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Science 88:629–633, 1995